Researchers at the Casey Eye Institute, Oregon Health & Science University (OHSU), Portland, USA, have provided formal results of a Phase 1/2 study, published at… Read More »A phase 1/2 multi-centre study provides results for the treatment of XLRP, promising a Phase 2/3 study to progress in 2025.
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company based in Iselin, New Jersey, USA, has announced that the UK NICE (National Institute for Health and… Read More »Outlook Therapeutics (NASDAQ: OTLK) announce first and only approved ophthalmic formulation of bevacizumab (for treatment of wet AMD) in the EU and UK.
Kanski’s Clinical Ophthalmology – A Systematic Approach, 10th edition, by John F. Salmon (Elsevier) The 10th edition of Kanski’s Clinical Ophthalmology is a comprehensive… Read More »Kanski’s Clinical Ophthalmology – A Systematic Approach, 10th edition, by John F. Salmon (Elsevier)
Dear EURETINA Members, A very warm welcome to the December 5th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »December 5th, 2024 “EURETINA-Brief”© Issue No. 305
A team of Korean researchers have published a study using an AI-model of optical coherence tomography (OCT) image data to predict AMD treatment outcomes following… Read More »Korean research team provide an Artificial intelligence (AI) tool for predicting the treatment response of nAMD based on OCT biomarkers.
Researchers at the Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea, have outlined an increasing future burden of depressive disorders, providing… Read More »An investigation of the association between Retinitis pigmentosa (RP) and depressive disorder, including a call for practical training and methods.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of… Read More »The CHMP (EMA) has issued a positive opinion for the marketing authorisation of FYB203, a biosimilar candidate to Eylea (Aflibercept).
Dear EURETINA Members, A very warm welcome to the November 21st, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »November 21st, 2024 “EURETINA-Brief”© Issue No. 304
Researchers at the Department of Ophthalmology, and the Center for Visual Science, University of Rochester, New York, have reported a study using induced pluripotent stem… Read More »A novel induced pluripotent stem cell model shows a mechanistic defect and potential therapy for AMD and related macular dystrophies.
Clinical researchers at the Department of Ophthalmology, Bascom Palmer Eye Institute, in the University of Miami, Florida, have presented an update on clinical trial endpoints… Read More »An update of clinical trial endpoints provide a dynamic trial environment across a range of inherited retinal degenerations (IRDs).
